Glioblastoma Multiforme Treatment Market, By Drug Type (Bevacozumab, Temozolomide And Carmustine) – Global Industry Insights, Trends And Forecast – 2017 To 2025

Created On: Jul-2018
Report ID: IR127
Format: PDF

Glioblastoma Multiforme Treatment Market: Introduction

Glioblastoma Multiforme is a type of tumor that starts developing from glial cells, which supports the health of nerve cells present inside the brain. GBM has become the most common type of brain tumor that can be either intratentorial (area located below tentorium cerebilli) or supratentorial (area located above the tentorium cerebilli). GBM primarily occurs in male that aged above 65 years.

Market Dynamics

The Glioblastoma Multiforme treatment market size is anticipated to grow over the forecast period, owing to the increase in number of GBM and brain tumor awareness programs and associations such as EndBrainCancer, GBM Heroes event. According to United Nations (UN) Organizations, in most low-income countries, the number of older persons is expected to triple by 2050. Rise in oncological incidences especially brain tumor, and increasing mortality rate due to brain tumor has generated the demand for effective treatment methods, which in-turn is expected to fuel the Glioblastoma Multiforme treatment market size. For instance, according to the National Brain Tumor Society, in 2018, 78,980 new cases of non-malignant, primary malignant and other central-nervous system tumors will be diagnosed in the United States. Increased research and clinical trials on treatment of GBM through immunotherapy, and gene therapy is expected to contribute in the growth of GBM treatment market. However, neurotoxicity caused by commercialized drug for GBM, coupled with lack of efficacy of GBM treatment which leads to increase in mortality rate may restrain the growth of global Glioblastoma Multiforme treatment market size.

Segment Analysis

Temozolomide, a chemotherapy drug is expected to hold the major revenue share in the global GBM treatment market over the forecast period, owing to the higher efficacy of drugs in the treatment of GBM and their lesser toxic nature. According to American Association for Cancer Research’s (AACR’s) journal Clinical Cancer Research, in pre-clinical studies Temozolomide showed its broad-spectrum anti-tumor activity towards a range of tumor types, it also demonstrated distribution to all tissues including penetration into the central nervous system.  The potential increase in drug’s efficacy when combined with radiotherapy and chemotherapy is expected to boost the growth of Temozolomide drug.

Regional Insight:

North America is expected to hold the major market share in the global Glioblastoma multiforme treatment market, due to increased clinical research trials on GBM treatment in the region, coupled with increasing geriatric population in United States. Increased governmental and non-profit organization’s aid in escalating the number of clinical trials by providing fundings to the clinical research organizations is also anticipated to fuel the growth of GBM treatment market in North America. For instance, in 2015, government of Canada in partnership with the Brain Canada and the Canadian Cancer Society announced to provide an additional fund of US$ 5 million for brain cancer research.

In Europe, the Glioblastoma multiforme treatment market share is witnessing growth due to the development in healthcare infrastructure, coupled with increased governmental support for the treatment of GBM. For instance, in May 2018 UK government announced that it will increase its investment in brain cancer research to US$ 67.82 million a year in honour of Dame Tessa Jowell, former cabinet minister of UK, who died of Glioblastoma multiforme brain tumor in May 2018.

Competitive Landscape:

Major players operating in Glioblastoma multiforme treatment market size include Sun Pharmaceutical Industries, Celldex Therapeutics, Inc., Pfizer Inc., F.Hoffmann La Roche, Bristol-Myers Squibb, Teva Pharmaceuticals, Exellixis Inc., AngioChem Inc., and Arbor Pharmaceuticals LLC. Major key players are focusing on registering novel drugs and treatment technologies for approval, in order to commercialize them and to provide patients with effective treatment options for brain tumor and GBM treatment. For instance, in July 2018, IsoRay Inc., received the clearance from the US Food and Drug Administration (FDA) for its GammaTile therapy, which is a brachytherapy technology for the treatment of recurrent brain tumors.

Our Research Approach Includes
  •  Market Outlining
  •  Framing discussion guide
  •  Data Validation
  • Data Analysis
  •  Re-Validation and Finalization of Data
  •  Report Insights and Publishing
Our Research Approach Includes
  •  Market Outlining
  •  Framing discussion guide
  •  Data Validation
  • Data Analysis
  •  Re-Validation and Finalization of Data
  •  Report Insights and Publishing
Reach Out to us